Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation Recipient · Cytomegalovirus · Donor · Solid Organ Transplantation Recipient · Adenovirus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Chris Ouellette, MD)
Contact: Study coordinator (Melinda Triplet, RN, BSN) · Melinda.Triplet@nationwidechildrens.org · 614-722-6039
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study leads

Sumithira Vasu, MBBS
Principal Investigator
Ohio State University Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Biphenotypic Leukemia · Acute Leukemia · Acute Leukemia of Ambiguous Lineage

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Washington D.C., United States

Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Recipient

Abroad (travel likely)Recruiting

Copenhagen, Denmark

VABu Conditioning in Elderly AML HSCT

Allogeneic Hematopoietic Stem Cell Transplantation Recipient · Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Suzhou, China